The Harvard oncomouse drew world attention to the issue of patentability of life forms.
Pierre-André Dubois and Kate McCallie explore the divergent approaches of patent authorities in the US, Canada and the EU
As the race among global leaders spurs exponential growth in nanotechnology, companies must keep watch on intellectual property issues emerging with the new field, explains Vicki Norton
Survival and success for biotech companies across the US and worldwide is a tenuous and arduous endeavor in today's economy. Robin Silva offers some tips on how to ride the wave successfully
The Hatch-Waxman Act in the US represented a careful balance of interests between the generic and brand name pharmaceutical manufacturers. William Feiler and Paula Wittmayer examine the Safe Harbor exemption and the challenges it represents to the biotech industry
Rapid innovation and intense investment in the biotech industry has required patent
protection to adjust accordingly. Antonina Pakharenko-Anderson explains how Ukraine is rising to the biotech challenge
A local farmer's appeal to Canada's Supreme Court in a case involving agribusiness leader Monsanto could set the limits of patent holders' rights. Sam Mamudi examines the dispute
Bruce Proctor has global responsibility for all IP matters at premium drinks company Diageo. He tells Ingrid Hering about the challenges of protecting a brand portfolio that includes Smirnoff, Baileys and Guinness
Improved trade mark legislation and a concentrated effort from rights owners are achieving results against
counterfeiting in China. The hope is now the Chinese
leadership will take a direct role in the campaign,
reports Ralph Cunningham
Interview: Judge Arjen Meij, Court of First Instance
With an increasing number of Community Trade Mark cases reaching the European courts, Stéphanie Bodoni asks judge Arjen Meij from the European Court of First Instance how well the system is coping
The registrability of ccTLDs as trade marks burst into the open in Singapore late last year. Though the applications were withdrawn, some legal issues remain outstanding, explains Bryan Tan
The GSM story is one of success for the market as well as investors in the technology and IP rights holders, and it will be for the market to resolve the forthcoming issues on 3G IP rights by tried and tested methods, argues Hugh Dunlop
Snapshots of INTA's 125th Annual Meeting in Amsterdam
Marion Rees, IP manager, Virax, Australia
November / December 2019
IP law: are the pressures taking their toll?
Following World Mental Health Day, Max Walters seeks the views of in-house professionals on whether they struggle with workplace pressures, and asks how to improve wellbeing
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2019 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International